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ABSTRACT
Enhanced expression of the KI , subunit of cyclic AMP-dependent pro
tein kinase type I has been correlated with cancer cell growth. We provide
evidence that RI., is a growth-inducing protein that may be essential for
neoplastic cell growth. Human colon, breast, and gastric carcinoma and
neuroblastoma cell lines exposed to a 21-mer human RIâ€žantisense phos-
phorothioate Oligodeoxynucleotide (S-oligodeoxynucleotide) exhibited
growth inhibition with no sign of cytotoxicity. Mismatched sequence (ran
dom) S-oligodeoxynucleotides of the same length exhibited no effect. The
growth inhibitory effect of RIâ€žantisense oligomer correlated with a de
crease in the Kl , inKNA and protein levels and with an increase in KlI
(the regulatory subunit of protein kinase type II) expression. The growth
inhibition was abolished, however, when cells were exposed simulta
neously to both Kl., and Kll , antisense S-oligodeoxynucleotides. The KM
antisense S-oligodeoxynucleotide alone, exhibiting suppression of KM
along with enhancement of KI. expression, led to slight stimulation of cell
growth. These results demonstrate that two isoforms of cyclic AMP recep
tor proteins, Kl., and KM â€ž¿are reciprocally related in the growth control
of cancer cells and that the KI, antisense Oligodeoxynucleotide, which
efficiently depletes the growth stimulatory Kl.,, is a powerful biological
tool toward suppression of malignancy.
INTRODUCTION
cAMP2 functions as a transducer of hormonal signals through bind
ing to its receptor protein, cAMP-dependent protein kinase (1). The
tetrameric protein kinase is composed of two C subunits bound to a R
subunit dimer. Activation occurs when two cAMP molecules bind to
each regulatory subunit of protein kinase, resulting in the release of a
C subunit. Thus, all actions of cAMP as second messenger that are
implicated in the regulation of various cellular functions, such as
metabolism, secretion, cell proliferation, ion channel regulation, and
gene induction, have been related to protein phosphorylation through
the activation of protein kinase (2). Consequently, the significance of
the presence of an R subunit in protein kinase has been confined to its
inhibition of the C subunit.
There are, however, two types of cAMP-dependent protein kinases,
type I and type II, in mammalian cells. These kinases are distinguished
by their different R subunits, RI and RII, that interact with an identical
C subunit (3). Through biochemical studies and gene cloning, four
isoforms of the R subunits, RIâ€ž,RIÃŸ,RIIâ€ž,and RIIÃŸ,have been
identified (4, 5). These R isoforms differ in tissue distribution (6, 7)
and in biochemical properties (3, 8). The two general isoforms of the
R subunit also differ in their subcellular localization. RI is found
throughout the cytoplasm, whereas RII localizes to nuclei, nucleoli.
Received 5/28/92; accepted 12/8/92.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance with
18 U.S.C. Section 1734 solely to indicate this fact.
1To whom correspondence should be addressed, at National Cancer Institute, National
Institutes of Health. Building 10, Room 5B38, Bethesda, MD 20892.
2 The abbreviations used are: cAMP, cyclic AMP: R. regulatory (subunit): C, catalytic
(subunit): RIâ€žand RIIp, regulatory subunits of cAMP-dependent protein kinase type I and
type II. respectively; HEPES. 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid; SDS,
-.HIHIHIdodecyl sulfate; SSC, standard saline citrate; cDNA, complementary DNA; S-
oligodeoxynucleotide, phosphorothioate oligodeoxynucleolide.
Golgi, and to the microtubule-organizing center (9-12). Thus, these
studies suggest specific roles of the different isoforms of the R sub-
unit, apart from inhibition of the C subunit in the regulatory function
of cAMP. An enhanced expression of RIâ€žsubunit has been shown (12,
13) in human cancer cell lines and in primary tumors, as compared
with normal counterparts, in cells after transformation with the Ki-ras
oncogene or transforming growth factor a, and upon stimulation of
cell growth with GM-CSF or phorbol esters; conversely, a decrease in
the expression of RIâ€žcorrelates with growth inhibition induced by
site-selective cAMP analogues in a broad spectrum of human cancer
cell lines (13). Moreover, an inverse relationship between RI (protein
kinase type I) and RII (protein kinase type II) has been noted during
ontogenic development and cell differentiation (12, 13).
We hypothesize that RI(I is an ontogenic growth-inducing protein,
and its constitutive expression disrupts normal ontogenic processes,
resulting in a pathogenic outgrowth, such as malignancy. To directly
determine whether RIâ€žhas a role in neoplastic cell growth, at least in
vitro, we used the antisense strategy (14). We exposed human cancer
cells to an antisense unmodified Oligodeoxynucleotide (15) and to a
phosphorothioate analogue complementary to the first 21 bases of the
human RI,, mRNA and examined the effects of this treatment on cell
growth and morphology. As controls, we used mismatched sequence
(random) and RIIP antisense (16) oligomers of the same length.
MATERIALS AND METHODS
The 21-mer oligodeoxynucleotides and their phosphorothioate analogues
used in the present study were synthesized (17) using a Milligen Biosearch
8700 DNA synthesizer (Bedford, MA) and purified by reverse-phase high-
performance liquid chromatography. The oligomers had the following se
quences: human Rlâ€žantisense, 5'-GGC-GGT-ACT-GCC-AGA-CTC-CAT-3'
( 15); RII0 antisense, 5'-CGC-CGG-GAT-CTC-GAT-GCT-CAT-3' (16); and the
mismatched sequence, random oligomer was a random mixture of all four
nucleotides at every position.
8-Cl-cAMP was obtained from the Division of Cancer Treatment, NCI
(Bethesda, MD). Pepstatin, antipain, chymostatin. leupeptin, and soybean
trypsin inhibitor were obtained from Sigma Chemical Company (St. Louis,
MO). 8-N,-['2P]cAMP (60.0 Ci/mmol) was obtained from ICN Pharmaceuti
cals. Inc. (Irvine, CA). Protein A-Sepharose CL-4B was purchased from Phar-
macia-LKB (Uppsala, Sweden). Eagle's minimum essential medium, heat-
inactivated fetal bovine serum, trypsin-EDTA solution, penicillin-streptomycin
solution. L-glutamine, HEPES buffer (l M stock solution, pH 7.3), and mini
mum essential medium nonessential amino acids were obtained from G1BCO-
BRL (Grand Island, NY).
Cell Culture. The LS-174T human colon carcinoma cell line (provided by
J. Greiner, National Cancer Institute) and SK-N-SH human neuroblastoma cell
line (provided by L. Neckers, National Cancer Institute) were grown in Eagle's
minimum essential medium supplemented with 10% heat- inactivated fetal
bovine serum. Eagle's minimum essential medium nonessential amino acids.
20 iriM HEPES, 2 msi glutamine, and penicillin-streptomycin. MCF-7 human
breast cancer cell line was grown in improved minimal essential medium
supplemented with 10% heat-inactivated fetal bovine serum, 20 IBMHEPES, 2
mM glutamine. and penicillin-streptomycin. TMK-1 human gastric carcinoma
cell line (provided by E. Tahara. Hiroshima University School of Medicine,
Hiroshima. Japan) was grown in RPMI 1640 with 10% heat-inactivated fetal
bovine serum, 1 m.Mglutamine. and penicillin-streptomycin.
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For cell growth experiments, 2-3 X IO5ceIls/60-mm dish were seeded, and
oligodeoxynucleotides were added at 4 h postseeding and then every 36 h
thereafter without changing medium. At desired times, cell counts in duplicate
were performed on a Coulter counter (Coulter Corp.. Hialeah. FL) after har
vesting cells with gentle trypsinization. Cell viability was assessed by trypan
blue dye exclusion.
Immunoprecipitation of Kl . and KM, cAMP Receptor Proteins after
Photoaffmity Labeling with 8-N.,-[32P]cAMP. Cell extracts were prepared at
0-4Â°C.The cell pellets (2 x K)6cells), after 2 washes with phosphate-buffered
saline, were suspended in 0.5 ml buffer Ten (161 (20 msi Tris-HCl, pH 7.4; 0.1
M NaCl; 1% NP-40; 0.5% sodium deoxycholate; 5 ITIMMgCl2; 0.1 m.Mpep-
statin; 0.1 HIMantipain: 0.1 ITIMchymostatin; 0.2 rtiM leupeptin; 0.4 mg/ml
aprotinin: and 0.5 mg/ml soybean trypsin inhibitor, filtered through a 0.45-usi
pore size membrane), passed through a 20-gauge needle 5 times using a I-ml
syringe, allowed to sit at 4Â°Cfor 15 min, and centrifuged for 5 min in an
Eppendorf microfuge at 4Â°C.The supernatant was used as lysate. Protein
concentration (usually between 1 and 5 mg/ml) was determined by the method
of Lowry el al. (18) using bovine serum albumin as standard. Photoaffmity
labeling and immunoprecipitation of cAMP receptor proteins followed the
method previously described (16). Anti-RI or anti-RII antiserum (provided by
S. O. Doskeland. University of Bergen. Bergen, Norway) and protein A-
Sepharose were used for immunoprecipitation. the dissolved immunoprecipi-
tates were subjected to SDS-polyacrylamide gel electrophoresis. and the re
solved proteins were electrotransferred to nitrocellulose sheets. Radioactivity
was detected by autoradiography using Kodak X-Omat film.
Poly(A)' RNA Preparation. Poly(A)* RNA was extracted from 2 X IO7
cells for each treatment by QuickPrep'M mRNA Purification Kit (Pharmacia.
Piscataway. NJ). according to the manufacturer's instructions. Briefly, the cells
were homogenized with 4 M guanidine thiocyanate and 0.5% Sarkosyl
(AAlauroyl sarcosine/Nav) and then loaded onto an oligo (dThd) cellulose
span column. After washing 3 times with high salt buffer [10 m.MTris-HCl
(pH 7.4), I ITIMEDTA, 0.5 M NaCl] and twice with low salt buffer [10 miÂ«
Tris-HCl (pH 7.4), 1 ITIMEDTA, 0.1 M NaCl]. poly(A)* RNA was recovered
by washing with elution buffer [10 ITIMTris-HCl (pH 7.4), I m.MEDTA] at
65Â°C.The RNA obtained was precipitated in ethanol with glycogen and po
tassium acetate.
Northern Blot Analysis. RNA pellets were suspended in 15 ul denaturing
buffer (50% formamide-2.2 M formaldehyde-10 ITIMsodium phosphate, pH
7.5), incubated at 55Â°Cfor 15 min, and quenched on ice. Loading buffer (50%
glycerol, 50% formamide, bromophenol blue: 7.5 ul) was added, and 10 ug
mRNA were resolved on a 1.5% agarose gel containing 6.7% formaldehyde
(v/v) and 20 ITIMsodium phosphate buffer, pH 6.8. The resolved RNA was
blotted onto a Biotrans (ICN) nylon membrane and cross-linked by UV irra
diation. After prehybridization in 5 X Denhardt's solution. 5 X SSC, 50 ITIM
sodium phosphate (pH 6.5), 0.1% SDS, 250 ug/ml herring sperm DNA. and
50% (v/v) formamide. the membrane was hybridized at 42Â°C in the same
buffer containing nick-translated cDNA probe (IO7 cpm probe/ml hybridiza
tion solution). The same nitrocellulose filters were sequentially hybridized to
the following ''P-labeled probes: RIâ€ž,l .5 kilobase cDNA clone, containing the
entire coding region for the human RI,, (19) (provided by T. Jahnsen, Institute
of Pathology. Rikshospitalet. Oslo. Norway); Ca, 1.1 kb, containing total
open-reading frame of human C,, cDNA (20) (provided by S. K. Hanks, The
Salk Institute, San Diego. CA); and human ÃŸ-actin(Oncor p7000 ÃŸ-actin).The
membrane was washed 4 times in 2 x SSC and 0.1% SDS at room temperature
for 5 min followed by 2 washes using 0.1X SSC and 0.1% SDS at 50Â°C.
Autoradiography was performed using XAR2 (Kodak) film.
RESULTS AND DISCUSSION
Nuclease resistance is one of the major factors to be concerned with
in the use of oligodeoxynucleotides for the antisense inhibition of
gene expression. The normal unmodified ÃŸ-oligodeoxynucleotides are
far more sensitive to nuclease hydrolysis than are a-oligodeoxynu-
cleotides, methylphosphonate, or phosphorothioate oligodeoxynucle
otides (14, 21, 22). In this study, we have chosen S-oligodeoxynucle-
otide to block the expression of RI,, subunit of protein kinase and
examined the effect of RI,, depletion on the cancer cell growth. We
also compared the effect of the S-oligodeoxynucleotide antisense on
cell growth with that of unmodified oligonucleotide.
LS-174T human colon carcinoma cells were exposed for 6 days to
RI,, antisense S-oligodeoxynucleotide at different concentrations, and
cell growth was compared with untreated cells. As shown in Fig. 1, the
concentration inducing 50% inhibition of cell proliferation of RI,,
antisense S-oligodeoxynucleotide was 6.0 UM.Trypan blue dye exclu
sion test showed that cells exposed to RI,, antisense oligomer up to 10
UMconcentration were more than 95% viable, but at 20 UMconcen
tration only 70% of cells were viable, indicating nonspecific cytotox-
icity of the oligonucleotide at higher concentrations. RI,, antisense
S-oligodeoxynucleotide induced growth inhibition in a time-depen
dent manner (Fig. 2). While untreated cells demonstrated an expo
nential rate of growth, cells exposed to 6 UMRIâ€žantisense oligomer
exhibited a reduced growth rate within 4-5 days and eventually
stopped proliferating by day 6. Since the half-lives of a S-oligodeox
ynucleotide in various biological fluids and sera have been shown to
be in the range of 7-19 h (22), and the RI,, antisense oligonucleotide
was added to the cell culture every 36 h, it is unlikely that the growth
inhibition observed (Fig. 2) was due to a nonspecific cytotoxicity
caused by the accumulation of the oligomer. Treatment with mis
matched (random) sequence S-oligodeoxynucleotide (6 UM) had no
appreciable effect on cell growth (Fig. 2). Interestingly, the growth
inhibitory effect of RIâ€žantisense oligomer was abolished when cells
were exposed simultaneously to both RI,, and RIIP antisense S-oli-
godeoxynucleotides; RIIP antisense oligomer alone had a slight stim
ulatory effect on cell growth (Fig. 2).
We next examined the effect of RI,, antisense oligodeoxynucleotide
unmodified and S-oligodeoxynucleotide on the growth of other human
cancer cell lines, including SK-N-SH neuroblastoma, MCF-7 breast,
and TMK-1 gastric carcinoma cells. As shown in Fig. 3. RI,, antisense
oligomer induced growth inhibition of these cells as potently as that
shown in LS-174T cells. Fig. 3 also shows that the unmodified anti-
sense oligomer at 30 UMproduced a growth inhibitory effect similar to
that caused by 6 UMS-oligodeoxynucleotide, demonstrating a greater
potency of phosphorothioate oligomer as compared with unmodified
oligomer. The growth inhibition was not due to nonspecific cytotox
icity, as cells were more than 90% viable after exposure to RI,,
antisense oligomer for 7 days. Mismatched (random) sequence oligo
mer of unmodified or phosphorothioate analogue at 30 and 6 UM
70
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Fig. I. Concentration dependency of RI(, antisense phosphorothioate oligodeoxynucle
otide on the growth inhibition of LS-174T colon carcinoma cells. Cells were exposed for
6 days with RIâ€žantisense oligomer at various concentrations, and cell counts were
performed in duplicate (see "Materials and Methods"). The percentage of growth inhibi
tion was obtained by comparing the growth of cells treated with the antisense oligomer to
that of untreated control cells. Data represent the average values Â±SD of three separate
experiments.
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concentrations, respectively, had no growth inhibitory effect up to 7
days of exposure (data not shown).
The growth inhibition induced by RI,, antisense oligodeoxynucle-
otide induced a change in cell morphology. SK-N-SH neuroblastoma
cells exposed to 6 UMRI,r antisense S-oligodeoxynucleotide for 6 days
exhibited a striking change in morphology: cells became flat, exhib
iting extremely enlarged cytoplasm (Fig. 4). In the case of HL-60
cells, the RI,, antisense oligodeoxynucleotide (15 UM)treatment for
4-5 days elicited a monocytic morphological change, indicating cell
differentiation (15).
To provide evidence that the growth inhibition induced in cells
exposed to RI,, antisense oligodeoxynucleotide was directly related to
the arrest of RI,, gene expression, we measured RI,, mRNA level. As
shown in Fig. 5, the human RI,, cDNA probe detected a major 4.4-
kilobase mRNA (23) in growing, untreated LS-174T cells (Fig. 5. RI,,,
Lane 4). Treatment with RI,, antisense S-oligodeoxynucleotide (6 U.M)
for 6 days resulted in almost complete blockage in the RI,, gene
expression (Fig. 5. RIâ€ž,Lane I ); the steady state level of RI,, mRNA
decreased to IQ% that of control cells (Fig. 5). Previous studies have
shown (24) that LS-174T cells contain mainly type I protein kinase,
and thus RI,, is the major, if not only. cAMP receptor in these cells. As
cells express R and C in a 1:1 ratio (25), it was expected that RI,,
antisense oligomer, which blocks RI,, expression, would also result in
suppression of C expression. In fact, C,, mRNA level decreased, in
parallel with the decrease in RI,, mRNA in cells exposed to RI,,
antisense S-oligodeoxynucleotide (Fig. 5, Câ€ž,Lane I ). In contrast,
exposure of cells to RIIP antisense S-oligodeoxynucleotide (6 UMfor
6 days), which led to a slight stimulation of cell growth (Fig. 2),
brought about an effect on RI,, and Câ€žmRNA opposite from that
induced by RI,, antisense oligomer: cells exhibited an enhanced ex
pression of RI,, and C,, mRNA (Fig. 5, Lane 2).
It has been shown (13, 26) that the striking growth-inhibitory effect
of site-selective 8-Cl-cAMP demonstrated in cancer cells correlates
with its selective modulation of two types of cAMP receptor proteins:
a marked down-regulation of RI,, receptor; and an up-regulation of
RII0 receptor. Present results show that the effect of RI,, antisense
oligonucleotide on the reduction of RI,, and C,, mRNA levels was
essentially the same as that exerted by 8-Cl-cAMP (Fig. 5. Lane 3).
Control
TIME (days)
Fig. 2. Time-dependen! growth inhibitory effect of RIâ€žantisense S-oligodeoxynucle
otide on LS-I74T colon carcinoma cells. Cells were untreated (O) or treated with 6 UM
S-oligodeoxynucleotide of RI(I antisense (O), 6 UMRUÃŸantisense (â€¢),6 UMRIâ€žantisense
+ 6 UMRIlp antisense (O), or with mismatched (random) sequence (A). At indicated
times, cell counts in duplicate were performed. Data represent the average values Â±SD
of three separale experiments.
Ã¬Control
234 0234
Time (Days)
Fig. 3. Effect of RItl antisense oligodeoxynucleotide on the growth of human cancer
cell lines. Cells were grown in the absence (Ol and presence of RI,, antisense oligode
oxynucleotide (LJ) or its phosphorothioute analog (A) at indicated doses (see "Materials
and Methods"). At indicated times, cell counts in duplicate were performed. Data repre
sent the average values Â±SD of three separate experiments.
These changing levels of RI,, and C,, mRNA were the specific effect
of the antisense oligonucleotides. as ÃŸ-actinmRNA level remained
fairly constant (Fig. 5).
We next examined the effect of the RI,, antisense oligonucleotide on
the levels of RIa and RUÃŸproteins in these cells using photoaffinity
labeling with 8-N,-['2P] cAMP followed by immunoprecipitation
with anti-RI and -RII antisera and SDS-polyacrylamide gel electro-
phoresis. In control LS-174T cells, the anti-RI antibody detected the
M, 48.000 protein, which comigrated with rabbit skeletal muscle RI,,,
that we refer to as RI,, (Fig. 6A ), while the anti-RII antibody, which
cross-reacts with both RII,, and RIIÃŸin human cells', detected only
one species of RII. the M, 52,000 protein, which did not comigrate
with the MT 54,000 bovine heart RII,,, that we refer to as RIIP
(Fig. 6ÃŸ).That the anti-RII-antibody failed to detect RII,,, which
exhibits M, 50,000-51,000 in human cells (9, 10, 27-30) and can be
phosphorylated to become M, 54,000 (30). indicates that these cells
contained RII,, at a low undetectable level. Treatment with RI,, anti-
sense S-oligodeoxynucleotide brought about a marked reduction in
RI,, level (Fig. 6A, Lane 2) with an increase in RIIÃŸlevel (Fig. 65,
Lane 2) as compared with untreated control cells. 8-Cl-cAMP treat
ment brought about an effect on RI,, and RIIÃŸlevels similar to that of
RI,, antisense oligomer (Fig. 6/1, B, Lane 4), whereas RIIÃŸantisense
S-oligodeoxynucleotide brought about effects opposite those of RI,,
antisense oligomer (Fig. 6,/4 and B, Lane 3) (16). The marked reduc
tion in the band detected with the anti-RII antibody (Fig. 6B, Lane 3)
in cells treated with RIIP antisense oligonucleotide further supports
that the anti-RII antibody detected RIIÃŸbut not RIIâ€žin LS-I74Tcells.
These results show that RI,, and RIIp antisense oligodeoxynucleotides
each exerted a specific effect on their respective target mRNAs and
that their targeting of either isoform of R subunit expression resulted
in compensatory enhancement of the expression of the other form of
R subunit. The arrest of RI,, gene expression was commonly observed
in SK-N-SH (Table 1), MCF-7 and TMK-I (data not shown) cancer
cells, those that exhibited growth arrest (Fig. 3) after exposure to RIâ€ž
antisense oligonucleotide. Importantly, however, when cells were
blocked from the expression of both RI,, and RIIÃŸgenes by exposure
' Cho-Chung el al., unpublished observation.
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Fig. 4. Change in morphology of SK-N-SH neuroblastoma cells treated with RIâ€žantisense S-oligodeoxynucleotide. Cells untreated (control) or treated for 6 days with RIâ€žantisense
oligomer, 6 UM.or mismatched sequence oligomer. 6 UM(random), were seeded at IO4 cells/ml onto 4-chamber tissue culture slides and grown for 48 h, Â±continued treatment with
the oligomers. Cells were fixed and stained by Wright's stain X 120.
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inhibition and differentiation in HL-60 cells in which C subunit ex
pression was not down-regulated and remained the same. Differenti
ation of HL-60 cells was abolished when cells were exposed to both
RIâ€žand RIIÃŸantisense oligomers, eliminating both RI,, and RIIÃŸ.
However, differentiation was not blocked when RI,, and RIIâ€žwere
eliminated by RIâ€žand RIIâ€žantisense oligomers. A situation similar to
exposure of cells to both RI,, and RIIÃŸantisense oligodeoxynucle-
otides was demonstrated by overexpression of RII,, in /m-transformed
â€¢¿â€¢2.2kbNIH3T3 cells in which RIâ€žand RIIÃŸwere reduced, but did not
produce growth inhibition or reverse transformation (31, 32). Thus,
the RIâ€žantisense oligonucleotide induced growth inhibition with or
without Câ€žsuppression. The common effect of RI,, antisense oligo
nucleotide was, however, down-regulation of RI,, with up-regulation
of RIIp.
As RIIa forms the more favored complex with the C subunit as
compared with other R subunits (4, 32), it may serve as a reservoir to
B
Fig. 5. Decreased Rlâ€žand Câ€žmRNA levels in LS-I74T colon carcinoma cells exposed
to RIa antisense oligodeoxynucleotide. Cells were treated for 6 days with RI,, antisense
S-oligodeoxynucleotide and RIIÃŸantisense S-oligodeoxynucleotide each at 6 UMconcen
tration (see "Materials and Methods") or with 8-Cl-cAMP (IO (JM) for 6 days (single
treatment at 5 h after seeding). Poly(A)* RNA was isolated from control (untreated) and
treated cells, and Northern blot analysis was performed as described in "Materials and
Methods." Lane I, cells exposed to RI,, antisense oligomer; Lane 2. cells exposed to RII0
antisense oligomer; Lane 3, cells treated with 8-CI-cAMP; Lane 4, untreated control cells.
The same nitrocellulose filters were sequentially hybridized to the 32P-labeled nick-
translated cDNA probes (see "Materials and Methods"). The data in the table represent
quantification by densitometric scanning of the autoradiograms. The data are expressed
relative to the levels in control cells, which are set equal to I arbitrary unit. The data
represent an average value of three separate experiments.
of cells to both Rl(, and RIIP antisense oligodeoxynucleotides simul
taneously, cells were no longer growth inhibited (Table I), demon
strating a clear reciprocal relationship between RIâ€žand RIIp expres
sion in growth control of these cells.
In LS-174T cells that contained mainly RIa, RIa antisense oligo
nucleotide treatment resulted in the suppression of both RIâ€žand C,t
subunits. Thus, growth inhibition induced by RIâ€žantisense oligomer
in LS-174T cells, at least in part, could be due to down-regulation of
Câ€žsubunit. However, no direct role of C subunit of protein kinase has
been shown (15) in the differentiation induced by RIâ€žantisense oli
gonucleotide in HL-60 leukemia cells that contained both RI,, and
RIIa. Suppression of RIâ€žby RI,, antisense oligodeoxynucleotide,
which brought about a compensatory increase in RIIP, induced growth
68â€”
43-
25.7â€”
â€”¿ â€¢¿â€¢â€”¿Â«-RI,, â€”¿- â€”¿Â«-Rnâ€ž
RIâ€ž Ru,, 1234 RI,. Ru,, 1234
Lane1234TreatmentControlRI,,
antisenseR
Dantisense8-CI-cAMPRelative
RI,,1.00.11.50.2LevelsRHâ€ž1.02.00.12.5
Fig. 6. Effect of RIQ antisense oligodeoxynucleotide on the levels of RI(I and RII^
cAMP receptor proteins in LS-174T colon carcinoma cells. Cells were treated with RIâ€žor
RIIp antisense S-oligodeoxynucleotide or with 8-CI-cAMP as described in Fig. 5. Prep
aration of cell extracts, the photoaffmity labeling with 8-NvP2P)cAMP. immunoprecip-
itation using the anti-RI or anti-RII antiserum and protein A-Sepharose, and the following
SDS- pol yaery lam ide gel electrophoresis were performed as described in "Materials and
Methods." Preimmune serum controls were performed simultaneously, and no immuno-
precipitated band was detected. Ria, the Mr 48,(XK)RI (Sigma); Klla. the Mf 56,(KK)RII
(Sigma). Lanes Ria and RIIa are from photoaffinity labeling only; A and B, Lanes 1-4,
photoaffinity labeling followed by immunoprecipitation with anli-RI and anti-RII antisera,
respectively. The data in the table represent quantification by densitometric scanning of
the autoradiograms. The data are expressed relative to the levels in control (untreated)
cells, which are set equal to ÃŒarbitrary unit. The data represent an average value of three
experiments.
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Table 1 Effect of Rlt, and KUÃŸantisense S-oligodeox\nucleotides added singly or in
combination on the growth and levels of RItt and Rllp in SK-N-SH neuroblastoma
cells
Cells were treated with Rla or RUÃŸantisense S-oligodeoxynucIeotide. singly or in
combination (see "Materials and Methods"). On day 5, preparation of cell extracts,
photoaffinity labeling with 8-N.v|i2P]cAMP. immunoprecipitation using the anti-Rl or
anti-RII antiserum and protein A-Sepharose, and the following SDS-polyacrylamide gel
eleclrophoresis were performed as described in "Materials and Methods." The data of
Rl(, and RUÃŸlevels represent quantification by densitometric scanning of the autorad-
iograms of SDS-polyacrylamide gel electrophoresis. The data are expressed relative to
the levels in control (untreated) cells, which are set equal to 1 arbitrary unit. The data
represent an average value of three separate experiments. On day 5, cell counts induplicate were performed (see "Materials and Methods"), and the percentage of cell
growth was obtained by comparing the growth of cells treated with oligodeoxynucleotide
to that of untreated control cells. Data represent the average values of three separate
experiments.
Relative levels
TreatmentControlR1â€žAS"
(5UM)Rllp
AS (5MM)RIâ€ž
AS (5 MM)+ Rllp AS (5MM)RIâ€ž
AS (5 MM)+ Random (5MM)Random
(10 MM)RIâ€ž1.00.21.30.20.21.0RUÃŸ1.02.00.20.21.81.0%
of cellgrowth10050110954592
" AS, antisense.
sequester the protein kina.se in an inactive holoenzyme. Thus, the ratio
of type I/type II protein kinase would be regulated mainly by the
amounts of RIâ€žand RIIp available, when RIIâ€žremains constant. That
the down-regulation of RIâ€žled to growth inhibition, as shown by RIâ€ž
antisense oligodeoxynucleotide or by 8-CI-cAMP treatment, suggests
that RIa is a positive regulator of cell growth. Down-regulation of
both RI(, and RIIp or RII^ alone leads to continued cell growth, while
Rlly overexpression results in growth inhibition (33), suggesting that
RIIp is a negative regulator of cell growth. The RIâ€žantisense oligode
oxynucleotide, which efficiently down-regulates RIâ€žand up-regulates
RIIp, in fact induced growth inhibition in a variety of cell types of
cancer cells.
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